For
UK
audiences
The professional's guide to product selection
The professional's guide to product selection
Antimuscarinic bronchodilator.
Acute bronchospasm by inhalation of nebulised solution
• Child under 5 years: 125–250 mcg, maximum 1 mg daily.
• Child 6–11 years: 250 mcg, maximum 1 mg daily.
• Over 12 years: 500 mcg, repeated as necessary, usual maximum 2 mg daily. Doses higher than the recommended maximum can be given under medical supervision.
Severe or life-threatening acute asthma
• Child 1 month–11 years: 250 mcg, every 20–30 minutes, for the first two hours, then repeat every 4–6 hours, as required.
• Over 12 years: 500 mcg, every 4–6 hours, as required.
For the management of reversible airway obstructions, particularly in COPD, and rhinitis.
Ipratropium can provide short-term relief in chronic asthma, but short-acting beta2 agonists are preferred as they act more quickly.
The aerosol inhalation of ipratropium can be used for short-term relief in mild COPD in patients who are not using a long-acting antimuscarinic drug. Its maximal effect occurs 30–60 minutes after use. Its duration of action is three to six hours and bronchodilation can usually be maintained with treatment three times a day.
Nebuliser liquid
Nebuliser liquid
250 mcg/1 ml, 20 doses
500 mcg/2 ml, 20 doses
Antimuscarinic bronchodilator.
• Over 18 years for maintenance of COPD: by inhalation of powder, one capsule, once daily.
Long-acting selective beta2 agonist with corticosteroid.
Prophylaxis of moderate-to-severe asthma for Aloflute® 25/125 by inhalation of aerosol
Adult: 2 inhalations twice daily.
Prophylaxis of moderate-to-severe asthma for Aloflute® 25/250 by inhalation of aerosol
Adult: 2 inhalations twice daily.
Long-acting selective beta2 agonist with long-acting muscarinic antagonist.
Adult: one inhalation twice daily.
Antimuscarinic bronchodilator.
• Over 18 years: by inhalation of powder, 375 mcg (1 inhalation), twice daily.
Short-acting selective beta2 agonist.
For acute bronchospasm, Salbulin Novolizer® by inhalation of powder
Adult: Initially 100–200 micrograms, up to 800 micrograms daily for persistent symptoms.
For prophylaxis of allergen- or exercise-induced bronchospasm, Salbulin Novolizer® by inhalation of powder
Adult: 200 micrograms.
Short-acting selective beta2 agonist.
Oral
(Please note, inhalation route preferred over oral route in children.)
• Child 1 month–1 year: 100 mcg/kg (maximum 2 mg) 3–4 times daily
• Child 2–5 years: 1–2 mg, 3–4 times daily
• Child 6–11 years: 2 mg, 3–4 times daily
• Child 12–17 years: 2–4 mg, 3–4 times daily
• Over 18 years: 4 mg (elderly and sensitive patients initially 2 mg), 3–4 times daily, with a maximum single dose of 8 mg (but unlikely to provide much extra benefit or to be tolerated).
Moderate to severe or life-threatening acute asthma, treated by inhalation of nebulised solution. Give via a large volume spacer, and via a close-fitting face mask in children under 3 years.
• Child 1 month–4 years: 2.5 mg, repeat every 20–30 minutes or when required.
• Child 5–11 years: 2.5–5 mg, repeat every 20–30 minutes or when required.
• Over 12 years: 5 mg, repeat every 20–30 minutes or when required.
Antimuscarinic bronchodilator.
• Over 18 years for maintenance of COPD: by inhalation of powder, one capsule, once daily.
Antimuscarinic bronchodilator.
• Over 18 years: by inhalation of powder, 375 mcg (1 inhalation), twice daily.
Antimuscarinic bronchodilator.
For the treatment of excessive respiratory secretions in palliative care by subcutaneous injection
Adult: 200 mcg every 4 hours and when required, hourly use is occasionally necessary, particularly in excessive respiratory secretions.
For the treatment of excessive respiratory secretions in palliative care by subcutaneous infusion
Adult: 0.6–1.2 mg/24 hours.
Antimuscarinic bronchodilator.
In the case of excessive respiratory secretions in palliative care by subcutaneous injection
Adult: 200 micrograms every 4 hours and when required, hourly use is occasionally necessary.
In the case of excessive respiratory secretions in palliative care by subcutaneous infusion
Adult: 0.6–1.2 mg/24 hours.
Antimuscarinic bronchodilator.
For the treatment of excessive respiratory secretions in palliative care by subcutaneous injection
Adult: 200 mcg every 4 hours and when required, hourly use is occasionally necessary, particularly in excessive respiratory secretions.
For the treatment of excessive respiratory secretions in palliative care by subcutaneous infusion
Adult: 0.6–1.2 mg/24 hours.
Antimuscarinic bronchodilator.
Reversible airway obstruction by inhalation of aerosol
• Child 1 month–5 years: 20 mcg, 3 times daily.
• Child 6–11 years: 20–40 mcg, 3 times daily.
• Over 12 years: 20–40 mcg, 3–4 times daily.
For reversible airways obstruction in COPD by inhalation of nebulised solution
• Adult: 250–500 mcg, 3–4 times daily.
For reversible airways obstruction in COPD by inhalation of aerosol
• Adult: 20–40 mcg, 3–4 times daily.
Severe or life-threatening acute asthma by inhalation of nebulised solution
• Child 1 month–11 years: 250 mcg, every 20–30 minutes, for the first two hours, then repeat every 4–6 hours, as required.
• Over 12 years: 500 mcg, every 4–6 hours, as required.
Acute bronchospasm by inhalation of nebulised solution
• Child 1 month–5 years: 125–250 mcg, maximum 1 mg daily.
• Child 6–11 years: 250 mcg, maximum 1 mg daily.
• Over 12 years: 500 mcg, repeated as necessary, usual maximum 2 mg daily. Doses higher than the recommended maximum can be given under medical supervision.
Rhinorrhoea associated with allergic and non-allergic rhinitis by intranasal administration
• Over 12 years: 2 sprays, 2–3 times/day into each nostril.